Back

Should we abandon EF to stratify heart failure treatment?

27 August 2017 (15:12 - 15:30)
Organised by:
Congress Presentation Part of: Heart failure with mid-range and preserved ejection fraction Miscellaneous ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Scott Solomon

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
State of the Art: HFmrEF - The new middle child
Professor R. De Boer (Rotterdam, NL)
Presentation thumbnail
Patterns and prognostic role of N-terminal pro-B-type Natriuretic Peptide in heart failure with mid-range vs. preserved vs. reduced ejection fraction
Doctor G. Savarese (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Prognostic relevance of the 40% left ventricular ejection fraction cut-off in chronic systolic heart failure
Doctor A. Aimo (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Prognostic relevance of preclinical diastolic dysfunction across left ventricular ejection fraction categories. The DAVID-Berg study
Doctor M. Gori (Bergamo, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure with mid-range and preserved ejection fraction

The Event

Event poster

ESC Congress 2017

27 August 2017 15:12 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources